Clusterin Is Required for β-Amyloid Toxicity in Human iPSC-Derived Neurons

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Alzheimer's disease (AD) pathogenesis is not fully understood, necessitating human-specific models.
• Clusterin (CLU) is a major genetic risk factor for AD, implicated in β-amyloid (Aβ) toxicity.

Purpose of the Study:

• To investigate the role of CLU in mediating Aβ-driven neurodegeneration in human induced pluripotent stem cell (iPSC)-derived neurons.
• To establish a CLU-knockout human iPSC line for studying Aβ neurotoxicity.

Main Methods:

• CRISPR/Cas9 gene editing to create CLU-knockout iPSCs.
• Differentiation of wild-type and CLU-knockout iPSCs into cortical neurons.
• Aβ peptide treatment and assessment of neurodegeneration via imaging assays.
• Gene expression analysis using qPCR and RNA sequencing.

Main Results:

• Aβ treatment caused dose-dependent neurodegeneration in wild-type neurons, with increased intracellular CLU.
• CLU-knockout neurons showed no significant neurodegeneration upon Aβ exposure.
• Transcriptomic analysis revealed dysregulation of AD, lysosome, and cytoskeletal pathways.

Conclusions:

• Clusterin is a critical mediator of Aβ-induced neurodegeneration in human neurons.
• CLU plays a significant role in the amyloid cascade of Alzheimer's disease.
• Targeting CLU may offer a novel therapeutic strategy for AD.